In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aardvark Therapeutics, Inc., with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju’s rating is based on several compelling factors that highlight Aardvark Therapeutics, Inc.’s potential in the obesity treatment market. The recent acquisition of Metsera by Pfizer for a substantial premium underscores the value of companies with promising obesity drug pipelines, enhancing Aardvark’s attractiveness. Aardvark’s ARD-201, an orally-bioavailable weight loss option, is particularly appealing due to its potential convenience over existing injectable treatments and its demonstrated efficacy in preclinical models.
Furthermore, Aardvark’s current valuation appears undervalued compared to its peers, suggesting a compelling buying opportunity. The company’s late-stage clinical development of ARD-101 and its proprietary combination with a DPP-4 inhibitor position it uniquely to target mass market obesity and associated conditions. The upcoming period is expected to be catalyst-rich, with several key clinical milestones and data readouts anticipated, which could further drive interest and valuation in the near future.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AARD in relation to earlier this year.